<PAGE>
UNITED STATES
SECURITIES & EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR QUARTER ENDED JUNE 30, 1998
COMMISSION FILE NUMBER: 0-23247
FOCAL, INC.
-------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 94-3142791
- ----------------------------------- --------------------
(State or other jurisdiction of (I.R.S. employer
incorporation or organization) identification no.)
4 Maguire Road, Lexington, MA 02173
---------------------------------------------------
(Address of principal executive offices
including zip code)
(781) 280-7800
-----------------------------------
(Registrant's telephone number including area code)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period of time that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for at least the past 90 days.
Yes |X| No |_|
As of June 30, 1998, the Registrant had 13,302,062 shares of Common Stock
outstanding.
<PAGE>
FOCAL, INC.
Form 10-Q for the Quarter Ended June 30, 1998
INDEX
PAGE NUMBER
INDEX 2
PART I - FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS
Condensed Balance Sheets at December 31, 1997
and June 30, 1998 3
Condensed Statements of Operations for the Three
Months and Six Months Ended June 30, 1997 and 1998 4
Condensed Statements of Cash Flows for the Six
Months Ended June 30, 1997 and 1998 5
Notes to Condensed Financial Statements 6
ITEM 2 - Management's Discussion & Analysis of Financial 8
Condition and Results of Operations
PART II - OTHER INFORMATION
ITEMS 1 - 6 14
SIGNATURES 15
2
<PAGE>
Focal, Inc.
Condensed Balance Sheets
<TABLE>
<CAPTION>
(Audited) (Unaudited)
December 31, June 30,
1997 1998
----------- -----------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents $26,810,777 $11,121,114
Marketable securities 6,428,374 19,244,306
Inventories 566,989 1,175,655
Accounts receivable and prepaid expenses 2,733,584 1,010,327
----------- -----------
Total current assets 36,539,724 32,551,402
Notes receivable from related parties 343,480 375,919
Property, plant & equipment, net 2,710,513 2,670,412
Other assets 12,696 13,032
----------- -----------
Total assets $39,606,413 $35,610,765
----------- -----------
----------- -----------
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable & accrued liabilities $4,031,807 $3,103,578
Deferred revenue 750,000 750,000
Current portion of capital lease obligations 890,451 889,907
----------- -----------
Total current liabilities 5,672,258 4,743,485
Capital lease obligations 1,421,983 1,373,055
Stockholders' equity:
Common stock 128,686 133,021
Additional paid-in capital 80,777,780 84,637,233
Notes receivable from related parties (1,688,057) (1,583,758)
Deferred compensation (768,865) (616,536)
Accumulated other comprehensive income (17,358) (20,765)
Accumulated deficit (45,920,014) (53,054,970)
----------- -----------
Total stockholders' equity 32,512,172 29,494,225
----------- -----------
Total liabilities and stockholders' equity $39,606,413 $35,610,765
----------- -----------
----------- -----------
</TABLE>
See accompanying notes.
3
<PAGE>
FOCAL, INC.
Condensed Statements of Operations
(unaudited)
<TABLE>
<CAPTION>
Three months Six months
ended June 30, ended June 30,
-------------------------- --------------------------
1997 1998 1997 1998
<S> <C> <C> <C> <C>
REVENUES:
Collaborative R&D revenues $1,950,333 $810,186 $10,854,562 $2,038,793
Product revenues -- 759,417 -- 1,471,637
----------- ----------- ---------- -----------
Total revenues 1,950,333 1,569,603 10,854,562 3,510,430
COSTS AND EXPENSES:
Cost of product revenues -- 822,373 -- 1,552,363
Research & development 3,648,129 4,076,026 6,888,762 8,033,787
General & administrative 717,407 970,880 1,499,628 1,905,783
----------- ----------- ---------- -----------
Total costs and expenses 4,365,536 5,869,279 8,388,390 11,491,933
Interest income (net) 203,302 393,690 419,872 846,546
----------- ----------- ---------- -----------
NET INCOME (LOSS) ($2,211,901) ($3,905,986) $2,886,044 ($7,134,957)
----------- ----------- ---------- -----------
----------- ----------- ---------- -----------
Basic and diluted net income (loss)
per share (proforma in 1997) ($0.21) ($0.29) $0.28 ($0.54)
----------- ----------- ---------- -----------
----------- ----------- ---------- -----------
Shares used in computing basic and diluted
net income (loss) per share 10,342,753 13,254,038 10,181,849 13,235,428
----------- ----------- ---------- -----------
----------- ----------- ---------- -----------
</TABLE>
4
<PAGE>
Focal, Inc.
Condensed Statements of Cash Flows
(Unaudited)
<TABLE>
<CAPTION>
Six months ended June 30,
1997 1998
-------------------------------
<S> <C> <C>
Operating Activities
Net income (loss) $2,886,044 ($7,134,957)
Adjustments to reconcile net loss to
net cash used in operating activities:
Depreciation and amortization 539,852 542,975
Amortization of deferred
compensation 134,329 152,329
Interest accrued on notes receivable (7,526) (56,999)
Increase (decrease) in cash arising
from changes of operating assets
and liabilities:
Inventories -- (609,666)
Accounts receivable and prepaid expenses (120,665) 1,723,257
Accounts payable and accrued liabilities 384,071 (928,229)
Deferred revenue 1,395,167 --
Notes receivable -- 24,560
-------------------------------
Net cash provided by (used in) operating activities 5,211,272 (6,285,730)
Investing activities
Purchase of marketable securities (8,074,222) (21,057,598)
Sale of marketable securities 5,296,166 8,238,260
Purchase of property and equipment (1,019,687) (502,874)
Other assets (314) (336)
-------------------------------
Net cash used in investing activities (3,798,057) (13,322,548)
Financing activities
Proceeds from equity financings,
net of issuance costs -- 3,549,500
Proceeds from exercise of
stock options 8,340 32,753
Proceeds from issuance of common stock
employee stock purchase plan -- 285,124
Issuance of note receivable (30,000) --
Principal payments on notes receivable -- 100,710
Proceeds from lease financing 477,930 499,797
Principal payments on capital lease
obligations (497,223) (549,269)
-------------------------------
Net cash provided by (used in) financing
activities (40,953) 3,918,615
-------------------------------
Net increase (decrease) in cash and cash
equivalents 1,372,262 (15,689,663)
Cash and cash equivalents at beginning
of the period 5,465,471 26,810,777
-------------------------------
Cash and cash equivalents at end of
the period $6,837,733 $11,121,114
===============================
Supplemental disclosure of cash flow information:
Property acquired under capital
lease obligations $379,639 $0
===============================
Interest paid $42,041 $107,473
===============================
</TABLE>
See accompanying notes.
5
<PAGE>
Notes to Condensed Financial Statements
June 30, 1998
(Unaudited)
Note 1. Basis of Presentation
Focal, Inc. develops, manufactures and commercializes, synthetic, absorbable,
liquid surgical sealants, tissue coatings and local drug delivery products,
based on its proprietary polymer technology. The Company's family of surgical
sealant products is being developed for use inside the body with or without
sutures and staples to seal air and fluid leaks resulting from lung, neuro,
cardiovascular and gastrointestinal surgery.
The accompanying unaudited, condensed financial statements have been prepared by
the Company in accordance with generally accepted accounting principles for
interim financial information and with the instructions to Form 10-Q.
Accordingly, they do not include all of the information and footnotes required
by generally accepted accounting principles for complete financial statements.
In the opinion of management, the accompanying financial statements include all
adjustments, including normal recurring accruals, considered necessary for a
fair presentation of the financial position, results of operations, and cash
flows for the periods presented.
The results of operations for the three months and six months ended June 30,
1998 are not necessarily indicative of the results that may be expected for the
entire fiscal year ended December 31, 1998.
These financial statements should be reviewed in conjunction with the audited
financial statements and notes thereto included in the Company's Annual Report
on Form 10-K for the year ended December 31, 1997.
Note 2. Net Income (Loss) Per Share
Basic and diluted net income (loss) per share is computed using the weighted
average number of shares of common stock and convertible preferred stock
outstanding, assuming conversion of preferred stock at date of issuance. Common
equivalent shares from stock options and warrants are excluded as their effect
is antidilutive or not material.
Note 3. Exercise of Overallotment Option from Initial Public Offering
In January 1998, the underwriters for the Company's initial public offering
exercised the Overallotment option on 375,000 shares of common stock granted to
them in connection with the offering. The Company received net proceeds of $3.5
million from the issuance of these shares.
6
<PAGE>
Note 4. Revenue Recognition for Product Sales
Revenues from product sales are recorded in full as product shipments are made,
as there are no contractual right of return or stock rotation privileges. All
product revenues recorded during the three month and six month periods ending
June 30, 1998 were attributable to sales to the Ethicon division of Johnson &
Johnson.
Note 5. Inventories
Inventories are stated at the lower of cost (first-in, first-out method) or
market. At December 31, 1997 and June 30, 1998, inventories consisted of the
following:
<TABLE>
<CAPTION>
December 31, June 30,
1997 1998
-------------------------------
<S> <C> <C>
Raw materials $566,989 $307,187
Work in process -- 839,634
Finished goods -- 28,834
-------------------------------
$566,989 $1,175,655
-------------------------------
-------------------------------
</TABLE>
Note 6. Adoption of Newly Issued Accounting Standards
In June 1997, the FASB issued Statement No. 130, "Reporting Comprehensive
Income." Statement No. 130 was adopted effective January 1, 1998 and there was
no material effect on the Company's financial statements, Statement No. 130
establishes standards for the reporting and display of comprehensive income and
its components. Statement No. 130 requires unrealized gains and losses on the
Company's marketable securities, which prior to adoption were reported
separately in stockholders' equity, to be included in other comprehensive
income.
The components of comprehensive income for the three and six month periods ended
June 30, 1997 and 1998 are as follows:
<TABLE>
<CAPTION>
Three months ended June 30,
1997 1998
-----------------------------------
<S> <C> <C>
Net loss $(2,211,901) $(3,905,986)
Other comprehensive income:
Change in unrealized loss on
marketable securities 26,644 2,602
-----------------------------------
Comprehensive loss $(2,185,257) $(3,903,384)
-----------------------------------
-----------------------------------
</TABLE>
7
<PAGE>
<TABLE>
<CAPTION>
Six months ended June 30,
1997 1998
-----------------------------------
<S> <C> <C>
Net income (loss) $2,886,044 $(7,134,957)
Other comprehensive income:
Change in unrealized loss on
marketable securities 8,583 (3,407)
-----------------------------------
Comprehensive income (loss) $2,894,627 $(7,138,364)
-----------------------------------
-----------------------------------
</TABLE>
Management's Discussion & Analysis of Financial Condition and Results of
Operations:
The following discussion should be read in conjunction with the accompanying
unaudited, condensed financial statements and the related footnotes thereto,
appearing elsewhere in this report. This Management's Discussion and Analysis
contains certain forward looking statements regarding future events with respect
to the Company. Actual events and/or future results of operations may differ
materially as a result of the factors described herein and in the Company's
Report on Form 10-K for the year ended December 31, 1997. Those factors
described under "Business -Product and Product Development programs,"
"-Strategic Alliances," "-Patents and Proprietary Rights," "-Government
Regulation," "-Competition and Technological Change," "-Third Party
Reimbursement" and "Factors Affecting Operating Results" in the Report on Form
10-K should be read in conjunction with this Management's Discussion and
Analysis.
Overview
The Company was founded in 1991, and is focused on the development, manufacture
and commercialization of synthetic, absorbable, liquid surgical sealants, tissue
coatings and local drug delivery products, based on the Company's proprietary
polymer technology. Since inception, the Company has funded its operations
primarily through the private placement of equity securities and most recently,
in December 1997, through an initial public offering of common stock. In
addition, the Company has entered into strategic alliances with corporate
partners and has recorded revenues totaling $23.5 million through June 30, 1998,
in conjunction with these alliances. The Company has incurred net losses in each
year since its inception, including net losses of approximately $3.9 million for
the three months ended June 30, 1998. At June 30, 1998, the Company had an
accumulated deficit of $53.1 million. The Company's operating losses have
resulted primarily from expenses incurred in connection with the Company's
research and development activities, including
8
<PAGE>
preclinical and clinical trials, development of manufacturing processes and
general and administrative expenses. The Company expects to incur net losses at
least through 1999 and may incur net losses in subsequent periods although the
amount of future net losses and time required by the Company to reach
profitability are highly uncertain. The Company is dependent upon corporate
partners for funding of a significant portion of research and development
expenses. If the Company does not continue to receive funding from its current
corporate partners, or is unable to otherwise obtain third party funding, net
losses will continue to increase. The Company's ability to achieve and sustain
profitability will be dependent upon obtaining regulatory approval for and
successfully commercializing its FocalSeal surgical sealants, and developing the
manufacturing capacity and sales and marketing capability for its products.
There can be no assurance that Focal will obtain the required regulatory
approvals, or successfully develop, manufacture, commercialize and market
products or that the Company will ever achieve profitability. In addition, if
the Company achieves profitability, there can be no assurance that such
profitability would be sustained.
The Company introduced its first commercial product, FocalSeal-L for lung
surgery indications, in Europe in March 1998 through its strategic marketing
alliance with the Ethicon division of Johnson & Johnson. The Company anticipates
that revenues derived from European sales of the Company's FocalSeal surgical
sealants will account for a substantial majority of the Company's near term
product revenues. The Company has obtained a CE mark to market FocalSeal
surgical sealant in the member countries of the European Union.
Results of Operations
Three months ended June 30, 1998, compared to three months ended June 30, 1997
Revenues for the three months ended June 30, 1998, decreased to $1.6 minion from
$2.0 million for the three months ended June 30, 1997. Included in the 1998
quarter were product revenues of $759,000 and collaborative revenues of $810,000
compared with $2.0 million of collaborative revenues during the same period in
1997. The quarterly funding under the alliance with Ethicon has decreased from
$1.25 minion per quarter in 1997 to $750,000 per quarter in 1998 pursuant to the
provisions of the Company's agreement with Ethicon. Additionally, the cessation
of a local drug delivery collaboration with Novartis contributed to the decline
in collaborative revenues in the second quarter of 1998 compared with the same
period in 1997.
Cost of goods sold for the quarter ended June 30, 1998 of $822,000 were recorded
relating to the commercial release of the Company's FocalSeal-L product. Gross
margins remained slightly negative due to the startup phase of the Company's
manufacturing operations and the resulting lack of economies of scale. There was
no cost of goods sold for the corresponding period in 1997 because the Company
had no revenues related to product sales
9
<PAGE>
Research and development expenses increased to $4,076,000 for the quarter ended
June 30, 1998, from $3,648,000 for the quarter ended June 30, 1997. This
increase resulted from the hiring of additional research and development
personnel, increased clinical trial expenses related to the Company's
FocalSeal-L surgical sealant for lung surgery, and increased pre-clinical
activities related to the Company's FocalSeal-S surgical sealant for
neurosurgery.
General and administrative expenses increased to $971,000 for the quarter June
30, 1998, from $717,000 for the quarter ended June 30, 1997. General and
administrative expenses during these periods consisted primarily of personnel
costs, which increased due to the hiring of additional personnel in
administration, human resources, and finance. In addition, certain costs related
to the transition of the Company to a publicly traded entity such as investor
relations, legal costs, and insurance have increased.
Interest income increased to $447,000 for the quarter ended June 30, 1998, from
$227,000 for the quarter ended June 30, 1997, as a result of higher average cash
balances, including the net proceeds from the Company's initial public offering
in December 1997.
The Company recorded a net loss of $(3,906,000) for the quarter ended June 30,
1998. During the same period in 1997, the Company recorded a net loss of
$(2,212,000). The increase in net loss is primarily attributed to decreasing
collaborative revenues and increased expenses relating to the company's research
programs from the second quarter of 1997 to the same period in 1998. The Company
expects that it will incur net operating losses through at least 1999.
Six months ended June 30, 1998, compared to six months ended June 30, 1997
For the six month periods ended June 30, 1998 and 1997, revenues decreased from
$10.9 million to $3.5 million. The decline in revenues was due primarily to the
inclusion in revenue for the 1997 period of a one-time payment of $7.0 million
in connection with the strategic alliance for surgical sealant products entered
into with Ethicon in January 1997. Included in revenues for the six months ended
June 30, 1998 were $1.5 million of product revenues in connection with
commercial introduction of the FocalSeal-L product in Europe by Ethicon.
Cost of goods sold for the six months ended June 30, 1998 of $1,552,000 were
recorded relating to the commercial release of the Company's FocalSeal-L
product. Gross margins remained slightly negative due to the startup phase of
the Company's manufacturing operations and the resulting lack of economies of
scale. There was no cost of goods sold for the corresponding period in 1997
because the Company had no revenues related to product sales.
10
<PAGE>
Research and development expenses for the six months ended June 30, 1998
increased to $8,034,000 from $6,889,000 for the corresponding period in 1997.
This increase resulted from the hiring of additional research and development
personnel, increased clinical trial expenses related to the Company's
FocalSeal-L surgical sealant for lung surgery, and increased pre-clinical
activities related to the Company's FocalSeal-S surgical sealant for
neurosurgery.
General and administrative expenses increased to $1,906,000 for the six months
ended June 30, 1998, from $1,500,000 for the six months ended June 30, 1997.
General and administrative expenses during these periods consisted primarily of
personnel costs, which increased due to the hiring of additional personnel in
administration, human resources, and finance. In addition, certain costs related
to the transition of the Company to a publicly traded entity have increased such
as investor relations, legal costs, and insurance.
Interest income increased to $954,000 for the six months ended June 30, 1998,
from $462,000 for the six months ended June 30, 1997, as a result of higher
average cash balances, including the proceeds from the Company's initial public
offering of common stock.
The company has recorded a net loss of $(7,135,000) for the six months ended
June 30, 1998 compared with net income of $2,886,000 for the same period in
1997. This net income was primarily the result of receipt of a one-time payment
of $7.0 million and quarterly funding of research and development expenses by
Ethicon. The Company expects that it will incur net operating losses through at
least 1999.
Liquidity and Capital Resources
Since its inception, the Company has financed operations primarily from the sale
of preferred stock in private placements as well as the Company's December 1997
initial public offering. Through June 30, 1998, the Company has raised
approximately $87.0 million from equity financings and has received $6.4 million
in equipment lease financing. In addition, the Company has received funding from
Ethicon and other corporate partners totaling approximately $23.5 million
through June 30, 1998. At June 30, 1998, the Company had cash, cash equivalents
and marketable securities of $30.4 million.
Cash used by operations totaled $6.3 million for the six months ended June 30,
1998 compared with cash provided by operations of $5.2 million for the same
period in 1997. The change in cash from operations was due to the net income
generated in the six months ended June 30, 1997 as a result of the $7.0 million
one-time payment from Ethicon. Cash provided by (used in) operations is equal to
the net income or loss
11
<PAGE>
incurred for each period, plus non-cash charges such as depreciation and
amortization of property and equipment plus any changes in working capital.
Capital expenditures from inception through June 30, 1998 totaled $6.9 million,
representing laboratory equipment, office furniture and equipment, computers and
certain leasehold improvements. The majority of these purchases have been
financed through either direct financing leases or sale and leaseback
arrangements. Capital expenditures for the six months ended June 30, 1998
totaled $503,000. As of June 30, 1998, the Company did not have any material
commitments for future capital expenditures. In the next 6 to 18 months, the
Company anticipates capital expenditures of approximately $2.5 million for
manufacturing facilities and approximately $1.2 million for related equipment.
The Company has commitments from lenders in the form of lease lines totaling
$1.5 million to provide for its expected capital needs during 1998, and expects
to secure additional lease lines to provide for its needs in 1999.
Based on a review of its existing information systems, the Company does not
anticipate that it will incur significant costs in connection with bringing its
information systems into compliance with year 2000 requirements. In addition,
the Company does not anticipate that it will be necessary for it to incur other
significant year 2000 related expenditures. The Company is currently evaluating
fully integrated enterprise resource planning systems and expects to install
such a system during 1999. A key requirement of such a system will be full year
2000 compliance.
The company believes that its existing capital resources, interest income and
future payments due under strategic alliances, will be sufficient to satisfy its
current and projected funding requirements for at least 21 months. Under the
Company's surgical sealant collaborative agreement with Ethicon, the Company
will receive fixed quarterly research and development funding of $750,000 per
quarter through 1998, for the Pulmonary and Neurosurgery products. In addition,
with the expansion of the agreement with Ethicon negotiated in July 1998, the
Company will receive approximately $2.6 million during the second half of 1998
and the first half of 1999 for research and development activities associated
with its cardiovascular sealant product. The Company may receive additional
payments under these agreements for research and development activities and upon
achievement of specified development milestones; however, as such payments are
dependent upon the achievement of such milestones, there can be no assurance as
to the receipt or timing of any such payments. Under certain agreements with
universities and consultants, the Company is obligated to make payments for
sponsored research and consulting services. The Company's research funding
commitments under these agreements totaled approximately $210,000 at June 30,
1998. Payments under these agreements are typically made on a quarterly or
monthly basis.
There can be no assurance that the Company's capital resources will be
sufficient to enable the Company to conduct its research and development
programs as planned.
12
<PAGE>
The Company's future capital requirements will depend on many factors, including
continued progress in its research and development programs, progress with
preclinical testing and clinical trials, the time and costs involved in
obtaining regulatory approvals, if any, the costs involved in filing and
prosecuting patent applications and enforcing patent claims, competing
technological and market developments, the establishment of additional strategic
alliances, the cost of manufacturing facilities and of commercialization
activities and arrangements, and the cost of product in-licensing and any
possible acquisitions. There can be no assurance that the Company's cash, cash
equivalents and marketable securities and interest income earned thereon,
together with funding that may be received under the Company's strategic
alliances, will be adequate to satisfy its capital and operating requirements.
The Company intends to seek additional funding through strategic alliances, and
may seek additional funding through public or private sales of the Company's
securities, including equity securities. In addition, the Company has obtained
equipment lease financing and other forms of debt financing and may continue to
pursue opportunities to obtain additional lease or debt financing in the future.
There can be no assurance, however, that additional equity or debt financing
will be available on reasonable terms, if at all. Any additional equity
financing would be dilutive to the Company's stockholders. If adequate funds are
not available, the Company may be required to curtail significantly one or more
of its research and development programs and/or obtain funds through
arrangements with corporate partners or others that may require the Company to
relinquish rights to certain of its technologies or product candidates.
13
<PAGE>
PART II. OTHER INFORMATION
Item 1. Legal Proceedings. None
Item 2. Changes in Securities and use of Proceeds.
There have been no material changes in the use of proceeds from the sale
of securities under the Company's Registration statement Form S-1 (333-38379),
which was declared effective on December 11, 1997, from that set forth in the
Company's report on Form 10-K for the year ended December 31, 1997.
Item 3. Defaults upon Senior Securities. None
Item 4. Submission of Matters to a Vote of Security Holders.
On May 27, 1998, the Company held its annual meeting of stockholders. The
following sets forth the items submitted to a vote of the stockholders of the
Company and the votes cast respect to such items,
1. Election of David M. Clapper and Fred E. Silverstein, M.D. as Class I
Directors of the Company:
David M. Clapper: 9,731,063 for
---------
115,006 vote withheld
---------
Fred E. Silverstein, M.D.: 9,744,724 for
---------
101,345 vote withheld
---------
2. Ratification of the appointment of Ernst & Young as independent
auditors of the Company for the fiscal year ending December 31,
1998:
9,840,784 for 4,200 against 1,085 abstain
Item 5. Other Matters. None
14
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this 10-Q report to be signed on its behalf by the
undersigned thereunto duly authorized.
Date: August 12, 1998 FOCAL, INC.
BY: /s/ W. Bradford Smith
----------------------------
W. Bradford Smith,
Vice President and Chief
Financial Officer
15
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C> <C> <C> <C>
<PERIOD-TYPE> 3-MOS 3-MOS 6-MOS 6-MOS
<FISCAL-YEAR-END> DEC-31-1997 DEC-31-1998 DEC-31-1997 DEC-31-1998
<PERIOD-START> APR-01-1997 APR-01-1998 JAN-01-1997 JAN-01-1998
<PERIOD-END> JUN-30-1997 JUN-30-1998 JUN-30-1997 JUN-30-1998
<CASH> 0 11,121,114 0 0
<SECURITIES> 0 19,244,306 0 0
<RECEIVABLES> 0 1,010,327 0 0
<ALLOWANCES> 0 0 0 0
<INVENTORY> 0 1,175,655 0 0
<CURRENT-ASSETS> 0 32,551,402 0 0
<PP&E> 0 6,940,972 0 0
<DEPRECIATION> 0 4,270,560 0 0
<TOTAL-ASSETS> 0 35,610,765 0 0
<CURRENT-LIABILITIES> 0 4,743,485 0 0
<BONDS> 0 0 0 0
0 0 0 0
0 0 0 0
<COMMON> 0 133,021 0 0
<OTHER-SE> 0 29,361,204 0 0
<TOTAL-LIABILITY-AND-EQUITY> 0 35,610,765 0 0
<SALES> 0 0 0 0
<TOTAL-REVENUES> 1,950,333 1,569,603 10,854,562 3,510,4300
<CGS> 0 0 0 0
<TOTAL-COSTS> 0 822,373 0 1,552,363
<OTHER-EXPENSES> 4,365,584 5,046,906 8,388,390 9,939,570
<LOSS-PROVISION> 0 0 0 0
<INTEREST-EXPENSE> 22,551 53,358 42,040 107,473
<INCOME-PRETAX> (2,211,901) (3,905,986) 2,886,084 (7,134,957)
<INCOME-TAX> 0 0 0 0
<INCOME-CONTINUING> (2,211,901) (3,905,986) 2,886,084 (7,134,957)
<DISCONTINUED> 0 0 0 0
<EXTRAORDINARY> 0 0 0 0
<CHANGES> 0 0 0 0
<NET-INCOME> (2,211,901) (3,905,986) 2,886,044 (7,134,957)
<EPS-PRIMARY> (0.21) (0.29) 0.28 (0.54)
<EPS-DILUTED> (0.21) (0.29) 0.28 (0.54)
</TABLE>
